This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grove, J. I. Articles by Searle, P. F. Search for Related Content PubMed PubMed Citation Articles by Grove, J. I. Articles by Searle, P. F.

Generation of Escherichia Coli Nitroreductase Mutants Conferring Improved Cell Sensitization to the Prodrug CB1954¹

The University of Birmingham Cancer Research United Kingdom Institute for Cancer Studies, Edgbaston, Birmingham B15 2TT [J. I. G., C. G. P. F. S.]; School of Biosciences, The University of Birmingham, Edgbaston, Birmingham B15 2TT [A. L. L., P. R. R., S. A. W., E. I. H.]; and ML Laboratories plc, The Science Park, University of Keele, Keele, Staffordshire, ST5 5SP [J. I. G., C. J. W.], United Kingdom

Escherichia coli nitroreductase (NTR) activates the prodrug CB1954 to a cytotoxic derivative, allowing selective sensitization of NTR-expressing cells or tumors to the prodrug. This is one of several enzyme-prodrug combinations that are under development for cancer gene therapy, and the system has now entered clinical trials. Enhancing the catalytic efficiency of NTR for CB1954 could improve its therapeutic potential. From the crystal structure of an enzyme-ligand complex, we identified nine amino acid residues within the active site that could directly influence prodrug binding and catalysis. Mutant libraries were generated for each of these residues and clones screened for their ability to sensitize E. coli to CB1954. Amino acid substitutions at six positions conferred markedly greater sensitivity to CB1954 than did the WT enzyme; the best mutants, at residue F124, resulted in 5-fold improvement. Using an adenovirus vector, we introduced the F124K NTR mutant into human SK-OV-3 ovarian carcinoma cells and showed it to be 5-fold more potent in sensitizing the cells to CB1954 at the clinically relevant prodrug concentration of 1 µM than was the WT enzyme. Enhanced mutant NTRs such as F124K should improve the efficacy of the NTR/CB1954 combination in cancer gene therapy.

This article has been cited by other articles:

				S.-C. Liu, G-O. Ahn, M. Kioi, M.-J. Dorie, A. V. Patterson, and J. M. Brown Optimized Clostridium-Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104 Cancer Res., October 1, 2008; 68(19): 7995 - 8003. [Abstract] [Full Text] [PDF]

				Y. Barak, S. H. Thorne, D. F. Ackerley, S. V. Lynch, C. H. Contag, and A. Matin New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution Mol. Cancer Ther., January 1, 2006; 5(1): 97 - 103. [Abstract] [Full Text] [PDF]